Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Diabetes Management: Revenue and profit increased due to strong sales, higher sales volume, favorable foreign exchange effects, cost reductions, and improved profitability following the transfer of the CGM business. Healthcare Solutions: Revenue and profit increased due to higher revenue from the clinical testing and CRO businesses, optimization of selling prices, and cost reductions. Diagnostics and Life Science: Revenue and profit increased due to price revisions, reductions in selling, general and administrative expenses, U.S. tariff refunds, and favorable foreign exchange effects.
No applicable matters (There are no applicable matters.)
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥90,672 million (YoY +8.1%) |
| Operating profit | ¥10,413 million (YoY +171.0%) |
| Ordinary income | ¥8,133 million |
| Profit attributable to owners of the parent | ¥6,338 million |
| Net income per share | ¥50.06 |
| Equity ratio | End of the current fiscal period 31.2 / End of previous period 29.8 |
| Total assets | ¥543,077 million |
| Net assets | ¥168,468 million |
| Cash flows from operating activities | ¥14,331 million |
| Cash flows from investing activities | ¥-3,313 million |
| Cash flows from financing activities | ¥-10,018 million |
| Cash and cash equivalents at end of period | ¥41,282 million |
| Full-year earnings forecast | Net Sales ¥359,700 million (YoY -1.3%) / Operating profit ¥27,000 million (YoY +19.0%) / Ordinary income ¥22,000 million (YoY +244.3%) / Net income ¥15,400 million |
| Revision to Earnings Forecast | Not disclosed |
| Annual Dividend Forecast | ¥42 → ¥42（0.0%） |
| Segment revenue | Diabetes Management ¥27,814 million (YoY +20.2%), Healthcare Solutions ¥30,976 million (YoY +1.6%), Diagnostics and Life Sciences ¥31,797 million (YoY +5.4%) |
| Segment profit | Diabetes Management ¥9,180 million (YoY +132.2%), Healthcare Solutions ¥1,097 million (YoY +27.6%), Diagnostics and Life Sciences ¥1,813 million (YoY +108.2%) |
| Regional sales | ¥35,930 million, ¥24,653 million, ¥18,943 million, ¥11,144 million |
| Depreciation and amortization | ¥6,691 million |
| Impairment loss | ¥-28 million |
| Disclosure regarding the going concern assumption | No applicable matters (There are no applicable matters.) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Name of newly added company Not disclosed / Excluded Company Name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (audience: Not disclosed) |
| Issued Shares at Period-End | 127,320,915 Shares |
| Treasury Shares at Period-End | 212,023 Shares |
| Factors Behind Changes in Business Performance | Diabetes Management: Revenue and profit increased due to strong sales, higher sales volume, favorable foreign exchange effects, cost reductions, and improved profitability following the transfer of the CGM business. Healthcare Solutions: Revenue and profit increased due to higher revenue from the clinical testing and CRO businesses, optimization of selling prices, and cost reductions. Diagnostics and Life Science: Revenue and profit increased due to price revisions, reductions in selling, general and administrative expenses, U.S. tariff refunds, and favorable foreign exchange effects. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company attributes the increases in revenue and profit to strong sales, higher sales volume, favorable foreign exchange effects, cost reductions, the effects of price revisions, improved profitability following the transfer of the CGM business, and the impact of U.S. tariff refunds.